Biogena Group Invest Ag Overview
Data conflict on market capitalisation. The Wiener Börse instrument page carries a reference price of 41.55, a market cap of EUR 5.9m and a YTD of −26.96% [S3]. These are inconsistent with all 2026 press coverage, which reports prices of roughly EUR 3–5.40, YTD gains of 76–83%, and a market cap of EUR 17.72m in June 2026 [S11][S13]. The exchange page appears to be a stale or cached snapshot and is disregarded here.
Biogena Group Invest AG is a thinly capitalised listed holding vehicle whose value derives almost entirely from its minority interest in the BIOGENA operating structure. Press reporting puts that interest at roughly 4% of the Austrian sales company [S4]. BIOGENA itself, founded in Salzburg in 2006 by Dr. Albert Schmidbauer, is Austria's market leader in science-based premium micronutrient preparations made on the "pure substance" principle, meaning no colourants or preservatives. It produces in Austria and sells in more than 70 countries [S30][S7]. The group reported revenue of about EUR 124.9m and EBITDA of about EUR 19.1m in FY2024/25 [S12]. It is pursuing a "Vision 2030" target of roughly EUR 500m in revenue through direct-to-consumer channels, German expansion, flagship "PLAZA" health destinations, and a first entry into pharmacies [S8][S10][S12][S23]. For investors, Group Invest is now a merger-arbitrage instrument: each share converts into 0.879197 Biogena Good Vibes shares upon registration [S30].
What the listed entity does.
-
Biogena Group Invest AG is a holding company with no operations of its own. When it listed in 2020, the Vienna Stock Exchange described it as the issuer behind the central operating Biogena Group Invest GmbH & Co KG [S2].
-
When it moved up to direct market plus, the exchange described it as a shareholder in the Biogena Group [S1].
-
Regional press (July 2026) reports that it holds roughly four percent of the Austrian sales subsidiary. International distribution runs through Biogena International, which sits entirely within the new top holding [S4].
-
Its standalone income is therefore participation income. An aggregator shows revenue of about USD 402k, EBITDA of about USD 340k and net income of about USD 336k for the latest fiscal year (fiscal year unspecified; n/v) [S25].
What the BIOGENA GROUP does: company's own description. The group describes itself as follows:
-
An internationally oriented "361° Health" company exporting to more than 40 countries (older profile text) [S3]. More recent filings say more than 70 countries [S30].
-
Its core business is developing, producing and selling science-based premium micronutrient preparations under the pure-substance principle. It also positions itself as a knowledge and service partner in health, nutrition and well-being [S3].
-
Stated focus areas are iron, mineral and osteoporosis product innovations, and integrated solutions in occupational health promotion and diagnostics [S3][S30].
-
In its September 2026 listing communication, it calls itself a health group focused on micronutrients, diagnostics, prevention, longevity and personal health guidance. It develops and produces in Austria and sells through digital channels, medical and therapeutic partners, pharmacies, and its own stores and PLAZAs [S21].
Business model. BIOGENA is a vertically integrated brand owner covering the full value chain:
Revenue model mix.
-
The group does not publish a product vs. service vs. subscription split (n/d).
-
Analytically, revenue is predominantly product sales of supplements, sold both B2B2C through practitioners and D2C through stores and online.
-
Diagnostics, PLAZA treatments, Academy training and workplace health programmes add a smaller services layer.
-
BIOGENA ONE is positioned as a "daily health routine" [S12]. This suggests recurring purchase behaviour, but no subscription revenue is disclosed.
Customer types and end-markets.
-
More than 1 million customers in over 70 countries [S20].
-
Physicians and therapists using products alongside medical treatment or for prevention [S3].
-
Health-conscious consumers, including sports, aesthetics and longevity segments.
-
Corporate clients (occupational health) [S30].
-
Pet owners (BIOGENA PETS) [S33].
Independent characterisation. BIOGENA sits at the premium, practitioner-endorsed end of the European supplements market. It is distinctive in combining three things: owned manufacturing, a practitioner channel, and an experiential retail format (PLAZAs offering diagnostics, cold saunas and oxygen chambers [S6]). Its scale is small compared with multinational consumer-health players. Its growth record is unusually strong:
-
Average growth of roughly 27% a year since founding [S28].
-
+44% in FY2024/25 [S6].
Its capital-markets profile is unconventional:
-
Retail "community financing" since 2015: more than EUR 17m raised over 16 rounds from about 2,100 private investors [S19].
-
Retail growth bonds [S28][S8].
-
A retail-heavy share offering in 2026 [S20].
Strategy
Stated strategy themes. These are paraphrased from company communications [S12][S20][S23][S6]:
-
Vision 2030. Grow revenue from approx. EUR 125m to approx. EUR 500m by 2030, without further production-capacity investment.
-
Direct-to-consumer expansion and long-term customer loyalty. BIOGENA ONE positioned as a daily health routine.
-
Germany as the primary international growth market. PLAZAs, sport sponsorship, pharmacy entry.
-
Pharmacy channel entry (Austria, Germany, Italy) from October 2026. Pharmacies are described as the main sales channel for supplements, and one BIOGENA has so far been absent from.
-
"Health destination" positioning. PLAZAs combining diagnostics, biohacking, longevity treatments and consultation.
-
Science and quality leadership. In-house science team, "radical quality", Austrian production.
-
Capital-markets ladder. The founder calls direct market plus a "good entry station" and signals larger ambitions. He has dismissed a foreign listing such as Nasdaq as not the benchmark.
-
Founder-led family company with a long-term orientation.
Initiatives in the last 24 months.
Medium-term financial targets. FY2025/26 revenue approx. EUR 150m; approx. EUR 500m by 2030. Germany: EUR 58.0m to EUR 335.5m by FY2029/30. No margin, cash-flow or leverage targets are disclosed. Cost programmes: none disclosed.
Products & Services
BIOGENA does not publish a consolidated product catalogue with launch years and pricing in investor materials. The catalogue below lists offerings identifiable in public sources. Specifications and pricing for individual SKUs are n/d in investor disclosures.
Quality evidence:
-
Seven test wins in the Austrian "Market-Test" survey in 2025 [S6].
-
More than 90% of customers say they would recommend the brand (company claim) [S6].
Product Portfolio
| Line / offering | Description | Key capabilities / specs | Target customer | Launch / latest version | Pricing model | Source |
|---|---|---|---|---|---|---|
Pure-substance micronutrient range (approx. 260 products) | Capsules/powders with no colourants or preservatives, made in Austria | Science-based formulation by an in-house team of about 25 scientists | Practitioners and patients; health-conscious consumers | Ongoing | Unit retail price (n/d) | [S28] |
Iron preparations | Focus area for innovation | Iron supplementation | Patients with iron deficiency (via practitioners) | — | — | [S3][S30] |
Mineral preparations | Focus area for innovation | Mineral supplementation | General / practitioner | — | — | [S3] |
Osteoporosis products | Focus area for innovation | Bone health | Older adults, practitioners | — | — | [S3][S30] |
BIOGENA ONE | Daily health routine product. New formula and brand identity in Aug 2026 | All-in-one daily micronutrient | Mass-premium D2C | Relaunch 11 Aug 2026 | — | [S12][S34] |
BIOGENA Aesthetics | Beauty / skin micronutrients | — | Beauty-oriented consumers | — | — | [S28] |
BIOGENA Sports | Performance and recovery products, supported by football partnerships | — | Athletes, clubs | — | — | [S28][S35] |
BIOGENA PETS | Pet health and nutrition | Expanded via HEROSAN cooperation | Pet owners | Before Aug 2026 | — | [S33] |
BIOGENA PLAZAs | Large-format "medical wellness / day spa" health destinations | Diagnostics, biohacking, treatments, consultation, cold saunas, oxygen chambers | Affluent urban consumers | Düsseldorf Oct 2025 (1,000 m²); Munich Sep 2026; Frankfurt planned | Treatment/service fees (n/d) | [S6][S20] |
Biogena Stores | Own retail stores | Consultation plus product sales | D2C | 17 stores (date n/d) | Retail | [S3] |
Webshop / e-commerce | Online D2C | +99% growth in Austria in FY2024/25 | D2C | Ongoing | Retail | [S6] |
MyBiogenaCoach | Digital advisory app | Personalised advice | D2C | Before Jan 2024 | — | [S18] |
Diagnostics | Lab / biomarker diagnostics | Health status testing | D2C, practitioners | — | — | [S20] |
Workplace health promotion | Corporate health programmes | Integrated B2B solutions | Employers | — | Contract (n/d) | [S2][S30] |
BIOGENA Academy | Knowledge transfer / training | Education | Practitioners, consumers | — | — | [S6] |
Biogena Good Health World | Experience centre with own production, Koppl | Visitor experience plus manufacturing | Consumers, partners | Before Jan 2024 | — | [S18] |
Financial Narrative
BIOGENA GROUP (operating economics; FY = 1 Oct–30 Sep)
The group publishes headline revenue and EBITDA, plus prospectus-level figures for FY2024/25. Full five-year audited statements are not publicly available in a form verifiable here.
Sources:
-
Revenue and EBITDA [S12][S10].
-
EBIT and net income [S10][S9]. These were reported in press coverage of the prospectus/H1 period and attributed to the latest reported period. EBITDA of 19.08 matches the FY2024/25 figure.
-
Margins are calculated by the analyst.
Data conflicts.
-
FY2024/25 revenue is reported as EUR 124.9m (trend.at, prospectus-based [S12][S17]) and as approx. EUR 125m (ORF via [S36]). The Salzburg Chamber of Commerce (WKO) cites EUR 116m in a November 2025 article [S6]. The EUR 116m figure likely refers to a narrower perimeter (e.g., Biogena brand sales before consolidation) or a preliminary figure. The prospectus figure of EUR 124.9m is preferred.
-
FY2023/24 revenue is not directly disclosed. A 2024 bond marketing piece targeted approx. EUR 80m, which would be more than 25% growth on the prior year [S28]. Back-calculation from 124.9 at +44% implies approx. EUR 86.7m, while 116 at +44% implies approx. EUR 80.6m. The discrepancy is unresolved, so FY2023/24 is marked n/d.
Guidance and targets.
Sources: [S10][S17][S28][S12].
-
The FY2027/28 target of EUR 205m comes from 2024 bond marketing [S28] and appears to have been superseded by the more ambitious Vision 2030.
-
Vision 2030 is approx. EUR 502m per trend.at [S12]. Der Standard via [S38] cites approx. EUR 500m for FY2030/31.
Balance sheet, cash flow and ratios (group). Total assets, cash, debt split, net debt, equity, goodwill, working capital, operating cash flow, capex, FCF, ROE/ROA/ROIC, liquidity and leverage ratios, interest coverage and cash conversion cycle are all n/d in public summary sources. Known capital-structure facts:
-
7.5% growth bond 2024–2029 [S28].
-
"Wachstumsanleihe III" fully placed early in July 2026 [S8]. A press headline refers to a EUR 20m bond being oversubscribed [S39].
-
Equity raise of approx. EUR 18m in fresh capital per the company listing release [S20]. Other outlets cite approx. EUR 25m [S23][S36]. EUR 25m was the maximum upsized volume; the company's own "almost EUR 18m" is preferred.
-
Credit agency KSV1870 assesses default probability at 0.19% (as of 2024) [S28].
-
Management says the 2030 target requires no further investment in production capacity [S23].
Commentary.
Growth: Growth accelerated to +44% in FY2024/25. Drivers were Austrian e-commerce (+99%) and international expansion (Germany, PLAZAs) [S6]. Guidance of approx. EUR 150m for FY2025/26 implies roughly +20%, a deceleration in percentage terms.
Profitability: EBITDA margin of approx. 15% is respectable. The steep drop to an EBIT margin of approx. 7% and a net margin of approx. 1.5% indicates heavy depreciation (owned production, Good Health World, PLAZA build-outs) and material financing costs from the 7.5% coupon bonds and community loans. These cost lines are inferred, since line items are n/d.
Inflection: The 2026 equity raise and listing mark a shift from debt-heavy retail financing toward equity. The step-change in channel strategy (pharmacy entry from October 2026) is the key operating inflection.
BIOGENA GROUP INVEST AG (standalone holding; FY ends 31 Jan)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Role | Ownership / note |
|---|---|---|
Biogena Good Vibes AG | Top holding of the BIOGENA GROUP. Listed 10 Sep 2026 | Majority founder/family-owned. Approx. 18% free float at listing |
Biogena International | International sales | 100% within the new holding |
Austrian sales subsidiary (BIOGENA GmbH & Co KG and related entities) | Austrian operations and sales. Issuer of the growth bonds | Group Invest holds approx. 4% (press) |
Biogena Group Invest AG | Listed minority holding vehicle | Merging into Good Vibes |
Biogena Management Holding GmbH | Vehicle for strategic minority investments (e.g., HEROSAN 13.7%) | Group entity |
BIOGENA One World Foundation | Charitable foundation (children's equal opportunities, environment, education) | Associated foundation |
Business Lines
| Business line (as named by the company) | Content |
|---|---|
BIOGENA core micronutrients | Pure-substance preparations (iron, minerals, osteoporosis focus) |
BIOGENA ONE | Daily all-in-one routine product. Relaunched Aug 2026 |
BIOGENA Aesthetics | Beauty-from-within line |
BIOGENA Sports | Sports nutrition / performance |
Biohacking, Diagnostics & PLAZAs | Diagnostics, cold saunas, oxygen chambers, treatments |
Workplace health promotion | Integrated B2B corporate health solutions |
BIOGENA PETS | Animal micronutrients (now linked to HEROSAN) |
BIOGENA Academy | Practitioner and consumer education |
Segment Overview
| Segment | FY2024/25 |
|---|---|
Group total revenue (EUR Mn) | 124.9 |
Income Statement and Margin Analysis (%)
| Metric | FY2024/25 |
|---|---|
Revenue (EUR Mn) | 124.9 |
Revenue growth YoY (%) | 44 |
EBITDA (EUR Mn) | 19.08 |
EBIT (EUR Mn) | 8.54 |
Net income (EUR Mn) | 1.82 |
EBITDA margin (%) | 15.3 |
EBIT margin (%) | 6.8 |
Net margin (%) | 1.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | FY2025/26 (guidance) | FY2027/28 (earlier target) | FY2029/30–2030/31 (Vision 2030) |
|---|---|---|---|
Group revenue (EUR Mn) | 150 | 205 | 500 |
Income Statement and Per-Share Data
| Metric | FY2023/24 | FY2025/26 |
|---|---|---|
Revenue / participation income (USD K, aggregator, n/v) | — | 402 |
EBITDA (USD K, aggregator, n/v) | — | 340 |
Net income (USD K, aggregator, n/v) | — | 336 |
Dividend per share (EUR) | 0.03 | 0.05 |
Shares outstanding (m, derived) | — | 3.99 |
Revenue by Region
| Region (EUR Mn) | FY2024/25 | FY2025/26 | FY2029/30 |
|---|---|---|---|
Germany revenue (plan/target) | — | 58.0 | 335.5 |
Group total revenue | 124.9 | 150 | 500 |
Share Price History
| Date | Price | Context |
|---|---|---|
Jul 2025 | 2.38 | 52-week / multi-year low |
Mid/late Jun 2026 | 3.32–3.44 | 52-week high; YTD approx. +11% |
Jun/Jul 2026 | 4.70 | 52-week high at the end of subscription; market cap EUR 17.72m |
Late Jul 2026 | 5.30–5.35 | After the capital raise |
Aug 2026 | 5.20–5.40 | YTD approx. +76% |
25 Sep 2026 | 5.35 | YTD approx. +81% |
28 Sep 2026 | 5.25 | EGM day; YTD approx. +78% |
Margin Analysis (%)
| Metric | 2026 YTD |
|---|---|
Share price change (%) | 78 |
Capital Markets
| Item | Value |
|---|---|
Exchange ratio | 0.879197 Good Vibes shares per Group Invest share |
Group Invest per-share value used in the merger | approx. EUR 4.39 |
Good Vibes per-share value used in the merger | approx. EUR 4.99 |
Look-through value at the Good Vibes day-one close (EUR 5.65) | approx. EUR 4.97 per Group Invest share |
Group Invest close on 28 Sep 2026 | EUR 5.25 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Equity value / Sales | 3.9x | 486 / 124.9 |
Equity value / EBITDA | 25.5x | 486 / 19.08 |
P/E | 267x | 486 / 1.82 |
Equity value / FY2025/26E sales | 3.2x | 486 / 150 |
Capital Instruments
| Instrument | Issuer | Coupon | Maturity | Size |
|---|---|---|---|---|
Wachstumsanleihe 2024–2029 | BIOGENA operating company | 7.5% | 2029 | — |
Wachstumsanleihe III | BIOGENA GmbH & Co KG | — | — | approx. EUR 20m (headline: oversubscribed) |
Community financing (16 rounds since 2015) | Group | — | — |
|
Analyst Conclusions
Management guidance:
-
FY2025/26 (to 30 Sep 2026) group revenue of approx. EUR 150m (about +20%) [S10][S38].
-
Approx. EUR 500m by 2030 (FY2030/31 per Der Standard) [S38].
-
Germany to reach EUR 335.5m by FY2029/30 [S38b].
-
No profit guidance.
Consensus: none available.
Bull case:
-
Proven compounding with operating leverage ahead. BIOGENA grew 44% in FY2024/25 at a 15% EBITDA margin. Management says the 2030 target needs no new production capacity [S23]. Depreciation-heavy EBIT and net margins could therefore widen sharply as volume runs through the existing plant.
-
Pharmacy entry is a step-change in addressable market. By management's own description, BIOGENA has so far been absent from the main supplement channel [S23]. Even modest shelf share in Germany, Austria and Italy could add revenue faster than D2C alone.
-
Germany flywheel. The PLAZA openings, Bundesliga partnerships and approx. EUR 58m Germany base [S6][S20][S34] create a credible platform for the planned 54% CAGR there.
Bear case:
-
Valuation already discounts success. At EUR 486m the group trades at approx. 25x trailing EBITDA and approx. 267x trailing net income. Those are growth-stock multiples for a company with a 1.5% net margin.
-
Funding intensity and leverage opacity. Repeated retail bonds (including at 7.5%) and community loans, combined with no published balance sheet or cash flow, mean leverage and free cash flow cannot be assessed.
-
Execution and channel conflict. Quadrupling revenue in about five years while launching pharmacies, rolling out PLAZAs and entering pets risks overstretching a founder-centric organisation of about 480 staff.
Catalysts and monitorables (next 12 months):
-
Firmenbuch registration, the last Group Invest trading day, and crediting of Good Vibes shares (Q4 2026 expected [S30]).
-
FY2025/26 results versus the approx. EUR 150m guidance, including the first full-year disclosure as a listed group holding.
-
Pharmacy-channel sell-in in AT/DE/IT (from Oct 2026).
-
Frankfurt PLAZA opening and Munich utilisation.
-
Any refinancing of high-coupon debt with the new equity.
-
Possible move to a higher-tier market segment [S23].
-
Contribution from the HEROSAN and Combyn investments.
Analyst verdict. Biogena Group Invest AG is no longer an investment case in its own right. It is a short-lived conversion instrument. Shareholders unanimously approved its absorption into Biogena Good Vibes AG at 0.879197 new shares per share, and the company is expected to disappear from the register and the exchange once the Firmenbuch entry occurs. Management guides that for Q4 2026, while one outlet suggests early 2027.
Anyone holding or analysing the BIO.VI line should therefore look through to Good Vibes, and two things follow. First, at the late-September close of EUR 5.25, Group Invest traded above the merger's own valuation of approx. EUR 4.39 per share. It also traded at or slightly above its look-through value at Good Vibes' debut close. Arbitrage upside appears limited, and Group Invest's thin liquidity adds friction.
Second, the underlying BIOGENA franchise is genuinely attractive. It is Austria's market leader, vertically integrated, practitioner-endorsed, growing 40%-plus with a loyal customer-shareholder base, and about to unlock the pharmacy channel.
The tension lies in price and transparency. A EUR 486–550m valuation equals roughly 4x sales and 25x EBITDA on a business that converted only about 1.5% of revenue into net profit in FY2024/25. That business has financed itself partly through 7.5% retail bonds, and the direct market plus regime does not oblige it to publish full balance-sheet and cash-flow detail. The Vision 2030 target of EUR 500m is ambitious: it requires about 32% compound growth and a sixfold scale-up in Germany.
Our synthesis is that the operating story merits attention, but the equity is priced for flawless execution and should be underwritten only after the first full-year listed disclosure. That disclosure needs to show debt, cash generation and early pharmacy traction. For Group Invest holders, the practical decision is simply whether to accept Good Vibes exposure through conversion or to exit before the last trading day. Neutral, high-uncertainty stance; key watch items are FY2025/26 results and the merger registration date.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Entity | Tenure | Prior roles / education |
|---|---|---|---|---|
Dr. Albert Schmidbauer | Founder and CEO, BIOGENA GROUP | Group / Good Vibes AG | Since founding 2006 | Holds a doctorate (field n/d). Founder |
Stefan Klinglmair | CEO / Management Board, Biogena Group Invest AG; IR contact; member of group management board | Group Invest AG / Group | n/d (led the uplisting) | — |
Julia Hoffmann | Member of group management board | Group | — | — |
Supervisory Board members | — | Both AGs | — | — |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Ownership | Relative positioning vs BIOGENA |
|---|---|---|---|
Pure Encapsulations | Practitioner-channel premium supplements | Nestlé Health Science | Global hypoallergenic, practitioner-led brand with much greater scale. Closest model analogue |
Orthomol | Premium micronutrient combinations, pharmacy-led | Private (Germany) | Dominant in German pharmacies, the channel BIOGENA is entering |
Doppelherz (Queisser Pharma) | Mass-market supplements, pharmacy and drugstore | Private (Germany) | Mass-market leader; lower price point |
Burgerstein (Antistress AG) | Premium micronutrients, pharmacy | Private (Switzerland) | DACH premium pharmacy peer |
Dr. Böhm (Apomedica) | Supplements, Austrian pharmacies | Private (Austria) | Austrian pharmacy-channel leader |
Sunday Natural | D2C premium natural supplements | Private (Germany) | Online D2C competitor in Germany |
Bayer Consumer Health (e.g., Supradyn, Elevit) | Vitamins and minerals | Bayer AG (listed) | Global scale and pharmacy power |
Haleon (Centrum) | Multivitamins | Haleon plc (listed) | Global mass-market leader |
dm-drogerie markt (Mivolis, private label) | Mass-market supplements | Private | Price competition in DACH drugstores |
Thorne | Premium science-based supplements, practitioner and D2C | Private (L Catterton) | US premium peer with an international push |
Peer Comparison FY2024
| Metric | BIOGENA (FY2024/25) | Pure Encapsulations |
|---|---|---|
Revenue | EUR 124.9m [S12] | n/d (not separately reported) |
Revenue growth | +44% [S6] | — |
EBITDA margin | approx. 15.3% (calculated) | — |



